CNST Insider Trading
CNST | Market Equity
Comprehensive Trading Performance Summary
The investment history of corporate insiders at CNST provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Market Equity sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2021-02-24 01:58 | 2021-02-19 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $37.64 | 10,270 | $386,592 | 0 | 0.0% |
| 2021-02-20 01:32 | 2021-02-17 | COLUMN GROUP L P | 10% owner | SELL | $36.95 | 10,000 | $369,503 | 99,155 | -9.2% |
| 2021-02-20 00:17 | 2021-02-17 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $37.58 | 1,510 | $56,741 | 0 | 0.0% |
| 2021-01-21 01:56 | 2021-01-19 | Valentine Karen | Officer - See Remarks | OPT+S | $33.97 | 17,203 | $584,463 | 0 | 0.0% |
| 2020-12-29 00:02 | 2020-12-21 | GOLDSMITH MARK A | Director, 10% owner | SELL | $35.02 | 4,020 | $140,769 | 139,043 | -2.8% |
| 2020-12-23 00:53 | 2020-12-21 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.11 | 5,720 | $200,805 | 0 | 0.0% |
| 2020-06-11 01:50 | 2020-06-08 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $37.55 | 589 | $22,118 | 0 | 0.0% |
| 2020-05-14 01:30 | 2020-05-12 | Audia James E | Director | SELL | $50.10 | 6,100 | $305,622 | 25,434 | -19.3% |
| 2020-05-14 01:30 | 2020-05-12 | Senderowicz Adrian | Officer - Chief Medical Officer | OPT+S | $50.18 | 9,357 | $469,488 | 15,884 | 0.0% |
| 2020-05-14 01:29 | 2020-05-11 | GOLDSMITH MARK A | Director, 10% owner | OPT+S | $50.05 | 4,325 | $216,474 | 143,063 | 0.0% |
| 2020-05-14 01:25 | 2020-05-11 | Raythatha Jigar | Director, Officer - See Remarks | OPT+S | $50.17 | 9,235 | $463,281 | 14,961 | 0.0% |
| 2020-05-13 04:41 | 2020-05-08 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $49.53 | 28,803 | $1,426,679 | 0 | 0.0% |
| 2020-05-07 23:39 | 2020-05-06 | Trojer Patrick | Officer - Chief Scientific Officer | OPT+S | $45.16 | 10,000 | $451,553 | 0 | 0.0% |
| 2020-05-07 23:34 | 2020-05-05 | Valentine Karen | Officer - See Remarks | OPT+S | $40.08 | 17,310 | $693,714 | 0 | 0.0% |
| 2020-05-07 23:28 | 2020-05-06 | Audia James E | Director | SELL | $45.15 | 7,500 | $338,600 | 31,534 | -19.2% |
| 2020-05-07 23:25 | 2020-05-05 | GOLDSMITH MARK A | Director, 10% owner | OPT+S | $43.97 | 14,608 | $642,368 | 143,063 | 0.0% |
| 2020-04-30 03:20 | 2020-04-27 | GOLDSMITH MARK A | Director, 10% owner | OPT+S | $40.12 | 400 | $16,049 | 143,063 | 0.0% |
| 2020-04-30 03:03 | 2020-04-27 | Valentine Karen | Officer - See Remarks | OPT+S | $40.13 | 400 | $16,052 | 0 | 0.0% |
| 2020-04-23 03:17 | 2020-04-20 | Valentine Karen | Officer - See Remarks | OPT+S | $33.65 | 789 | $26,550 | 0 | 0.0% |
| 2020-04-21 00:53 | 2020-04-17 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.29 | 760 | $26,820 | 0 | 0.0% |
| 2020-04-21 00:52 | 2020-04-16 | Valentine Karen | Officer - See Remarks | OPT+S | $34.27 | 5,298 | $181,577 | 0 | 0.0% |
| 2020-04-16 21:31 | 2020-04-14 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.20 | 1,225 | $43,123 | 0 | 0.0% |
| 2020-04-13 23:56 | 2020-04-09 | Valentine Karen | Officer - See Remarks | OPT+S | $35.02 | 635 | $22,236 | 0 | 0.0% |
| 2020-04-13 23:55 | 2020-04-09 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.02 | 700 | $24,513 | 0 | 0.0% |
| 2020-03-24 01:57 | 2020-03-19 | COLUMN GROUP L P | 10% owner | BUY | $22.48 | 41,674 | $936,927 | 6,051,376 | +0.7% |
| 2020-03-11 23:11 | 2020-03-09 | Valentine Karen | Officer - See Remarks | OPT+S | $32.03 | 617 | $19,763 | 0 | 0.0% |
| 2020-02-15 01:09 | 2020-02-12 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.05 | 6,624 | $232,163 | 0 | 0.0% |
| 2020-02-15 01:09 | 2020-02-12 | Valentine Karen | Officer - See Remarks | OPT+S | $35.06 | 5,973 | $209,386 | 0 | 0.0% |
| 2020-02-13 01:36 | 2020-02-10 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $35.04 | 8,842 | $309,816 | 0 | 0.0% |
| 2020-02-13 01:36 | 2020-02-10 | Valentine Karen | Officer - See Remarks | OPT+S | $34.08 | 22,646 | $771,864 | 0 | 0.0% |
| 2019-12-17 01:57 | 2019-12-13 | EVNIN ANTHONY B | Director | BUY | $34.50 | 400,000 | $13,800,000 | 5,742,765 | +7.5% |
| 2019-12-17 01:56 | 2019-12-13 | Venrock Healthcare Capital Partners III, L.P. | 10% owner | BUY | $34.50 | 400,000 | $13,800,000 | 4,016,873 | +11.1% |
| 2019-11-14 04:31 | 2019-11-08 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 10% owner | SELL | $30.50 | 187,116 | $5,706,626 | 2,110,290 | -8.1% |
| 2019-11-13 05:19 | 2019-11-08 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 10% owner | SELL | $30.29 | 1,087,116 | $32,931,679 | 2,111,290 | -34.0% |
| 2019-11-09 01:28 | 2019-11-06 | Senderowicz Adrian | Officer - Chief Medical Officer | OPT+S | $28.12 | 27,232 | $765,848 | 15,884 | 0.0% |
| 2019-11-09 01:01 | 2019-11-06 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $21.50 | 65,626 | $1,410,775 | 0 | 0.0% |
| 2019-11-09 01:01 | 2019-11-06 | Trojer Patrick | Officer - Chief Scientific Officer | OPT+S | $25.07 | 46,142 | $1,156,854 | 0 | 0.0% |
| 2019-11-09 01:00 | 2019-11-06 | Audia James E | Director | SELL | $18.55 | 22,500 | $417,411 | 39,034 | -36.6% |
| 2019-11-09 01:00 | 2019-11-06 | Raythatha Jigar | Director, Officer - See Remarks | OPT+S | $28.33 | 102,750 | $2,911,380 | 14,961 | 0.0% |
| 2019-11-08 00:44 | 2019-11-05 | Reeve Emma | Officer - Chief Financial Officer | OPT+S | $15.50 | 1,000 | $15,504 | 0 | 0.0% |
| 2019-11-07 00:26 | 2019-11-05 | Audia James E | Director | SELL | $15.01 | 2,288 | $34,351 | 61,534 | -3.6% |
| 2019-11-07 00:26 | 2019-11-04 | Trojer Patrick | Officer - Chief Scientific Officer | OPT+S | $15.00 | 1,250 | $18,756 | 8,222 | 0.0% |
| 2019-10-24 22:45 | 2019-10-22 | Trojer Patrick | Officer - Chief Scientific Officer | OPT+S | $15.01 | 10,285 | $154,361 | 8,222 | 0.0% |
| 2019-10-24 22:44 | 2019-10-22 | Audia James E | Director | SELL | $15.01 | 5,212 | $78,242 | 63,822 | -7.5% |
| 2019-10-08 00:35 | 2019-10-03 | COLUMN GROUP L P | 10% owner | BUY | $8.50 | 1,411,764 | $11,999,994 | 159,155 | +100.0% |
| 2019-10-05 00:33 | 2019-10-03 | EVNIN ANTHONY B | Director | BUY | $8.50 | 2,823,529 | $23,999,997 | 5,342,765 | +112.1% |
| 2018-07-25 02:19 | 2018-07-23 | THIRD ROCK VENTURES LP | 10% owner | BUY | $15.00 | 266,667 | $4,000,005 | 2,983,051 | +9.8% |
| 2018-07-25 02:15 | 2018-07-23 | TEPPER ROBERT I | Director, 10% owner | BUY | $15.00 | 266,667 | $4,000,005 | 2,983,051 | +9.8% |
| 2018-07-24 23:46 | 2018-07-23 | ORBIMED ADVISORS LLC | 10% owner | BUY | $15.00 | 200,000 | $3,000,000 | 417,921 | +91.8% |
| 2018-07-24 03:15 | 2018-07-23 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 10% owner | BUY | $15.00 | 133,333 | $1,999,995 | 2,297,406 | +6.2% |
How to Interpret $CNST Trades
Not every insider transaction in CNST is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CNST shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for CNST
Insider activity data for CNST is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CNST, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.